Hansa Biopharma AB
Hansa Biopharma AB (publ), a biopharmaceutical company, develops immunomodulatory treatments for enabling transplants and rare immunoglobulin G (IgG)-mediated autoimmune conditions, gene therapy, and cancer using its proprietary enzyme technology platform. The company's lead drug candidate is Imlifidase, an antibody cleaving enzyme therapy that is in phase 3 clinical trial for use in sensitized kidney transplantations patients, as well as for anti-GBM antibody disease; and phase 2 clinical trial for antibody-mediated kidney transplant rejection and Guillain Barré syndrome. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), which is cancer immunotherapy. The company has a preclinical research collaboration agreement with argenx BV to evaluate the therapeutic potential of combining the two companies' IgG-modulating technologies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden. Show More...
-
Website https://www.hansabiopharma.com
-
Sector Healthcare
-
Industry Biotechnology
-
Last Quote 23.18 SEK
-
Last Updated 30-05-2025
-
External Links Yahoo Finance Morningstar Ratios
-
Interest Coverage
The interest coverage ratio is a debt ratio and profitability ratio used to determine how easily a company can pay interest on its outstanding debt.
Reference: Investopedia -
2010-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 TTM Earnings Per Share SEK -2.27 -1.69 -0.71 -0.71 -1.09 -2.12 -3.37 -4.96 -6.47 -9.0 -9.52 Dividends SEK Payout Ratio % * Shares Mil 8.0 15.0 23.0 25.0 27.0 31.0 33.0 36.0 38.0 40.0 40.0 Book Value Per Share * SEK 4.28 3.36 2.86 2.29 2.59 7.1 3.96 4.44 12.67 16.69 11.84 Free Cash Flow Per Share * SEK -1.71 -1.61 -1.02 -0.87 -0.63 -1.69 -2.61 -4.33 -4.77 -8.04 Return on Assets % -49.62 -62.45 -30.87 -30.13 -55.27 -47.61 -41.56 -35.65 -30.52 -44.75 -52.99 Financial Leverage (Average) 1.18 1.18 1.04 1.11 1.09 1.06 1.1 1.08 1.1 1.18 1.14 Return on Equity % -66.02 -73.49 -33.62 -32.25 -60.83 -50.71 -44.88 -38.64 -33.27 -50.61 -58.2 Return on Invested Capital % -66.02 -73.49 -34.32 -32.24 -60.2 -50.62 -44.79 -38.46 -33.14 -50.19 -57.16 Interest Coverage -235.11 -253.24 -350.29 -770.66 Current Ratio 0.25 0.47 8.36 0.38 2.71 14.25 9.99 14.32 11.98 6.51 8.4 Quick Ratio 0.25 0.47 8.1 0.08 2.42 14.15 9.92 14.28 11.92 6.39 8.4 Debt/Equity 0.010 0.010